XML 127 R115.htm IDEA: XBRL DOCUMENT v3.22.2.2
Supplemental Financial Information - Cash Flows (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Cash flows from operating activities          
Net income $ 282.4 $ 547.4 $ 1,126.1 $ 2,384.8  
Adjustments to reconcile net income to net cash flows from operating activities:          
Depreciation and amortization     102.7 40.5  
Right-of-use asset impairment, net of broker fees     0.0 24.8  
Equity-based compensation 54.2 42.4 139.3 122.0  
Non-cash performance allocations and incentive fees     184.1 (1,662.3)  
Non-cash principal investment income     (483.8) (458.3)  
Other non-cash amounts     (27.4) 20.7  
Purchases of investments     (559.6) (178.0)  
Proceeds from the sale of investments     388.3 533.8  
Payments of contingent consideration     (5.7) (50.0)  
Changes in deferred taxes, net     (2.3) 449.1  
Change in due from affiliates and other receivables     (62.6) (21.4)  
Change in deposits and other     (12.8) (23.3)  
Change in accounts payable, accrued expenses and other liabilities     (27.7) 90.9  
Change in accrued compensation and benefits     (265.3) 17.3  
Change in due to affiliates     2.4 1.4  
Change in lease right-of-use assets and lease liabilities     (7.0) 5.9  
Change in deferred revenue     274.9 247.6  
Net cash provided by (used in) operating activities     (258.5) 1,302.4  
Cash flows from investing activities          
Purchases of corporate treasury investments, net     (69.6) 0.0  
Purchases of fixed assets, net     (25.0) (27.0)  
Purchase of Abingworth, net of cash acquired     (150.2) 0.0  
Purchase of CBAM intangibles and investments, net     (618.4) 0.0  
Net cash used in investing activities     (863.2) (17.8)  
Cash flows from financing activities          
Borrowings under credit facilities     0.0 70.0  
Issuance of 4.625% subordinated notes due 2061, net of financing costs     0.0 484.1  
Payments on CLO borrowings     (8.9) (231.5)  
Proceeds from CLO borrowings, net of financing costs     55.2 87.5  
Payments of contingent consideration     0.0 0.1  
Dividends to common stockholders     (325.4) (266.7)  
Payment of deferred consideration for Carlyle Holdings units     (68.8) (68.8)  
Contributions from non-controlling interest holders     282.1 57.2  
Distributions to non-controlling interest holders     (173.5) (76.3)  
Common shares issued for performance allocations     38.9 0.0  
Common shares repurchased     (146.9) (84.5)  
Change in due to/from affiliates financing activities     (13.2) 21.8  
Net cash provided by financing activities     88.9 157.9  
Effect of foreign exchange rate changes     (79.8) (26.2)  
Increase (decrease) in cash, cash equivalents and restricted cash     (1,112.6) 1,416.3  
Cash, cash equivalents and restricted cash, beginning of period     2,475.1 989.6  
Cash, cash equivalents and restricted cash, end of period 1,362.5 2,405.9 1,362.5 2,405.9  
Reconciliation of cash, cash equivalents and restricted cash, end of period:          
Cash and cash equivalents 1,361.9 2,399.0 1,361.9 2,399.0 $ 2,469.5
Restricted cash 0.6 6.9 0.6 6.9 5.6
Total cash, cash equivalents and restricted cash, end of period 1,362.5 2,405.9 1,362.5 2,405.9 2,475.1
Cash and cash equivalents held at Consolidated Funds 177.2 134.8 177.2 134.8 147.8
MRE          
Cash flows from investing activities          
Proceeds from sale, net of cash sold     0.0 5.9  
Brazil management entity          
Cash flows from investing activities          
Proceeds from sale, net of cash sold     0.0 3.3  
Consolidated Operating Entities          
Cash flows from operating activities          
Net income     1,112.1 2,383.9  
Adjustments to reconcile net income to net cash flows from operating activities:          
Depreciation and amortization     102.7 40.5  
Right-of-use asset impairment, net of broker fees     0.0 24.8  
Equity-based compensation     139.3 122.0  
Non-cash performance allocations and incentive fees     179.4 (1,662.3)  
Non-cash principal investment income     (434.9) (470.7)  
Other non-cash amounts     (27.4) 20.7  
Purchases of investments     (582.4) (250.9)  
Proceeds from the sale of investments     410.2 559.1  
Payments of contingent consideration     (5.7) (50.0)  
Changes in deferred taxes, net     (2.3) 449.1  
Change in due from affiliates and other receivables     (62.0) (21.1)  
Change in deposits and other     (12.8) (23.3)  
Change in accounts payable, accrued expenses and other liabilities     (27.7) 90.9  
Change in accrued compensation and benefits     (265.3) 17.3  
Change in due to affiliates     2.4 1.4  
Change in lease right-of-use assets and lease liabilities     (7.0) 5.9  
Change in deferred revenue     274.9 247.6  
Net cash provided by (used in) operating activities     793.5 1,484.9  
Cash flows from investing activities          
Purchases of corporate treasury investments, net     (69.6) 0.0  
Purchases of fixed assets, net     (25.0) (27.0)  
Purchase of Abingworth, net of cash acquired     (150.2) 0.0  
Purchase of CBAM intangibles and investments, net     (618.4) 0.0  
Net cash used in investing activities     (863.2) (17.8)  
Cash flows from financing activities          
Borrowings under credit facilities     0.0 70.0  
Issuance of 4.625% subordinated notes due 2061, net of financing costs     0.0 484.1  
Payments on CLO borrowings     (8.9) (231.5)  
Proceeds from CLO borrowings, net of financing costs     55.2 87.5  
Payments of contingent consideration     0.0 0.1  
Dividends to common stockholders     (325.4) (266.7)  
Payment of deferred consideration for Carlyle Holdings units     (68.8) (68.8)  
Contributions from non-controlling interest holders     7.2 13.1  
Distributions to non-controlling interest holders     (52.5) (56.3)  
Common shares issued for performance allocations     38.9 0.0  
Common shares repurchased     (146.9) (84.5)  
Change in due to/from affiliates financing activities     (471.6) 21.8  
Net cash provided by financing activities     (972.8) (31.4)  
Effect of foreign exchange rate changes     (70.1) (19.4)  
Increase (decrease) in cash, cash equivalents and restricted cash     (1,112.6) 1,416.3  
Cash, cash equivalents and restricted cash, beginning of period     2,475.1 989.6  
Cash, cash equivalents and restricted cash, end of period 1,362.5 2,405.9 1,362.5 2,405.9  
Supplemental non-cash disclosures          
Issuance of common shares related to the acquisition of CBAM and Abingworth     219.5 0.0  
Reconciliation of cash, cash equivalents and restricted cash, end of period:          
Cash and cash equivalents 1,361.9 2,399.0 1,361.9 2,399.0  
Restricted cash 0.6 6.9 0.6 6.9  
Total cash, cash equivalents and restricted cash, end of period 1,362.5 2,405.9 1,362.5 2,405.9 $ 2,475.1
Cash and cash equivalents held at Consolidated Funds $ 177.2 $ 134.8 177.2 134.8  
Consolidated Operating Entities | MRE          
Cash flows from investing activities          
Proceeds from sale, net of cash sold     0.0 5.9  
Consolidated Operating Entities | Brazil management entity          
Cash flows from investing activities          
Proceeds from sale, net of cash sold     $ 0.0 $ 3.3  
Consolidated Operating Entities | Subordinated Notes Due 2061          
Reconciliation of cash, cash equivalents and restricted cash, end of period:          
Interest rate (percent)   4.625%   4.625%